🐇 Rapid #GDMT in HF with EF<50% (about 15 weeks) #medsky

Implementation= effective, safe, and associated with HF improvement

💊ARNi 52% vs 8%

💊Beta-blockers 78% vs 6.2%

💊MRA 98% vs 15.6%

💊#flozins 92% vs 6.2%

www.jacc.org/doi/full/10....

Need weekend plans?

Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease

Happy reading!

bit.ly/4iMNijV

INCH-HD - Australasian Kidney Trials Network (AKTN) The INCremental dialysis to improve Health outcomes in people starting Haemodialysis (INCH-HD) study: a randomised controlled trial

We also recently transitioned a pt to both - incremental HDF 💧💦 Some are very CONVINCEd in our dept but we may INCH closer to finding an answer #AKTN aktn.org.au/inch-hd/ pubmed.ncbi.nlm.nih.gov/36938090/ @sarahkmels.bsky.social @nephmadness.bsky.social

Round#2 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs ask are u CONVINCEd we have enough 💦 in the tank for HDF? Or less is more? It's a Brave New World with CAR-T cell therapy! Oxalate offenders - u can still have milk with your tea/coffee ☕😂 @nephmadness.bsky.social @nephjc.bsky.social

Huge findings in Lancet. What does this mean? Aging of our organs is driving the development of diseases like COPD, CKD, heart failure, and liver failure. Interventions that slow biological aging could reduce the risk for many of the most common chronic diseases.

www.thelancet.com/journals/lan...

#NephMadness 2025: Hemodialysis – The Future of Dialysis Personalization Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025   Mariana Murea @MarianaMurea Mariana Murea is an Associate Professor, nephrologist, and clinician-scientist at Wake …

I hope the dialysis region of #Nephmadness sparks a generation of innovators.

A dialysis that is improving by leaps and bounds will lift patients, Nephrology, and medicine in its wake.

ajkdblog.org/2025/03/10/n...

Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social

Round#1 #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of @nephmadness.bsky.social

Round#1 of #NephMadness @Wollongong #Nephospital AU🦘🐨us #Nephgongs wonder if Gila monster will strike again? How would we have managed if ex-tropical cyclone #Alfred had come to town?(my thoughts with those in northernNSW & QLD).Do you think alike?Look fwd to another month of@nephmadness.bsky.social

A golden year of innovative kidney disease therapeutics - Nature Reviews Nephrology In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a soluble g...

A golden year of innovative kidney disease therapeutics 👩‍🔬🥼👨‍🔬🧪 #Kidneydisease #NephSky #CardioSky #cardiovascular #Nephropathy @natureportfolio.bsky.social 👇👇👇

www.nature.com/articles/s41...

Summary of core principles of randomized control trial design and conduct with examples.

This is a must read for all #NephSky RCT readers (and RCT wannabe doers) from the Oxford trials folks in @ndt-era.bsky.social #OpenAccess

academic.oup.com/ndt/article/...

Table with core problems in RCTs and how to solve them

1/

Volume 40 Issue Supplement_1 | Nephrology Dialysis Transplantation | Oxford Academic An official journal of the European Renal Association - European Dialysis and Transplant Association. Publishes peer-reviewed original clinical and laboratory research across the full range of nephrol...

This is from a Bayer funded (but not Bayer influenced) @ndt-era.bsky.social supplement on trials and combination therapies in CKD

With really good reviews from experts incl @brendonneuen.bsky.social and many more

academic.oup.com/ndt/issue/40...

#NephSky

Cristina Popa 🦋 on X: "@_jeffreyha @AJKDonline @Nephro_Sparks @anna_burgner @KidneyWars @Elena_Cervants @jrkott27 @Kidney_Trials And since we are on the topic of dialysis, maybe add some HDF into the mix? Mostly since soon, it will be available in the US either?" / X @_jeffreyha @AJKDonline @Nephro_Sparks @anna_burgner @KidneyWars @Elena_Cervants @jrkott27 @Kidney_Trials And since we are on the topic of dialysis, maybe add some HDF into the mix? Mostly since soon, it will be available in the US either?

x.com/NephroSeeker...

@nephroseeker.medsky.social I'm excited for the HDF vs incremental HDx matchup!

Specialists split on AF management in advanced kidney disease Renal physicians and cardiologists diverge sharply on management of atrial fibrillation in advanced kidney disease, with key differences in prescribing of antithrombotic therapy and oral anticoagulati...

thelimbic.com/nephrology/s...

Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand The results of this survey of nephrology and cardiology clinicians across Australia and New Zealand highlights inter- and intraspecialty heterogeneity in risk assessment and primary prevention of AF-...

This recent survey in Australia New Zealand shows that #nephrologists and #cardiologists are split on the management of AF in advanced kidney disease. How do we provide multidisciplinary care to this high-risk group until more trial evidence is forthcoming?
onlinelibrary.wiley.com/doi/10.1111/...

📢 New Systematic Review & Meta-Analysis in
@kireports.bsky.social 📢

We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵

www.kireports.org/article/S246...

Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...

The latest from my team in Nature Medicine.

We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).

By @Biostayan, Taeyoung Choi and me

A 🧵
www.nature.com/articles/s41...

We treat patients, not lab results” can be augmented to “We treat patients, not P values.”

evidence.nejm.org/doi/full/10....

#MedSky @nejm.org @drmarthagulati.bsky.social @mmamas1973.bsky.social @cardioobdoc.bsky.social @shelleyzieroth.bsky.social

SAVE THE DATE: #NephMadness is just around the corner!

https://bit.ly/4frRAv3 (FREE)

@annaburgner.bsky.social @jrkott27.bsky.social @nephrosparks.bsky.social @kidneywars.bsky.social @nephmadness.bsky.social

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta-analysis, we assessed long-term saf...

Are you using HIF-PHIs?

(I would love to try in predialysis and PD mostly, but the companies didn’t even bother coming to 🇨🇦)

(Disclosure we wrote this: evidence.nejm.org/doi/abs/10.1... mostly Jeff Ha and @sunilbadve.bsky.social )

Exciting to see so much change since I wrote my first review for MedicineToday as a trainee on CKD management. Fast forward a few yrs & I'm looking fwd to more evidence to implementing these pillars of therapy for Diabetic Kidney Disease! @catherinezheng.bsky.social @brendonneuen.bsky.social